drugset / Trial / NCT04514081
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
RandomizedParallel-groupOpen-labelTreatment
Summary
This open-label, randomized, two-arm, phase 2 study has the primary objective of comparing the ORR obtained with Chidamide+Decitabine+Camrelizumab against that obtained with Decitabine+Camrelizumab in patients with Hodgkin Lymphoma who were confirmed resistant to Anti-PD-1 antibody therapy.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2022-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | — | Oral |
| Comparator | Camrelizumab | Monoclonal antibody | — | — |
| Comparator | Decitabine | Small molecule | — | — |